GSK4024484C

GSK4024484C is an investigational small molecule antimalarial being developed by GSK. It functions as a whole cell inhibitor of *Plasmodium falciparum*, the parasite responsible for the most severe and deadly form of malaria. The compound is currently in Phase I clinical development, where it is being evaluated in first-time-in-human studies to assess its safety, pharmacokinetics, and the effect of food on its oral absorption in healthy adult participants. GSK4024484C appears to be part of an alliance or in-license relationship, as indicated in GSK's pipeline reports, and represents a novel approach to targeting the malaria parasite at the whole-cell level.